Instrument Inactif

Communiqués Chinook Therapeutics, Inc.

Actions

KDNY

US16961L1061

Recherche biotechnologique et médicale

Communiqués

14/08/23	Novartis Completes Acquisition of Chinook Therapeutics	AQ
08/08/23	Chinook: Q2 Earnings Snapshot	AQ
28/07/23	Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy	AQ
22/07/23	CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook Therapeutics, Inc. - KDNY	BU
17/06/23	Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress	AQ
14/06/23	CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook Therapeutics, Inc. - KDNY	BU
13/06/23	Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront	AQ
13/06/23	£2.5b acquisition to boost Novartis' renal portfolio	AQ
12/06/23	Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress	AQ
12/06/23	Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG	AQ
25/05/23	CHINOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Chinook Therapeutics, Inc. on Behalf of Chinook Stockholders and Encourages Investors to Contact the Firm	BU
16/05/23	Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease	AQ
09/05/23	Chinook: Q1 Earnings Snapshot	AQ
09/05/23	Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates	AQ
05/05/23	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
05/05/23	Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress	AQ
27/04/23	Chinook Therapeutics to Present at Upcoming Investor Conferences	AQ
13/04/23	CHINOOK THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
13/04/23	Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors	AQ
11/04/23	Chinook Therapeutics to Present at Upcoming Investor Conferences	AQ
11/04/23	Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers	AQ
07/04/23	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	AQ
28/03/23	Chinook Therapeutics to Present at the Guggenheim Healthcare Talks \| Genomic Medicines and Rare Disease Days	AQ
23/03/23	Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023	AQ
13/03/23	CHINOOK THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)	AQ